Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Standard BioTools (NASDAQ: LAB) signed a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The deal is expected to close in roughly 30 days, subject to customary conditions, with the business operating under Standard BioTools until then. No purchase price was disclosed.
Key figures
- Expected close
- approximately 30 days
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.